Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Mar;6(1):20-7.
doi: 10.2174/1874471011306010004.

Biodistribution and dosimetry of (177)Lu-tetulomab, a new radioimmunoconjugate for treatment of non-Hodgkin lymphoma

Ada H V Repetto-Llamazares  1 , Roy H Larsen, Camilla Mollatt, Michael Lassmann, Jostein Dahle
Affiliations
Free PMC article

Biodistribution and dosimetry of (177)Lu-tetulomab, a new radioimmunoconjugate for treatment of non-Hodgkin lymphoma

Ada H V Repetto-Llamazares et al. Curr Radiopharm. 2013 Mar.
Free PMC article

Abstract

The biodistribution of the anti-CD37 radioimmunoconjugate (177)Lu-tetraxetan-tetulomab ((177)Lu-DOTA-HH1) was evaluated. Biodistribution of (177)Lu-tetraxetan-tetulomab was compared with (177)Lu-tetraxetan-rituximab and free (177)Lu in nude mice implanted with Daudi lymphoma xenografts. The data showed that (177)Lu-tetulomab had a relevant stability and tumor targeting properties in the human lymphoma model. The half-life of (177)Lu allowed significant tumor to normal tissue ratios to be obtained indicating that (177)Lu-tetraxetan-tetulomab could be suitable for clinical testing. The biological and effective half-life in blood was higher for (177)Lu-tetraxetan-tetulomab than for (177)Lu-tetraxetan-rituximab. The biodistribution of (177)Lu-tetraxetan-tetulomab did not change significantly when the protein dose was varied from 0.01 to 1 mg/kg. Dosimetry calculations showed that the absorbed radiation doses to normal tissues and tumor in mice were not significantly different for (177)Lu-tetraxetan-tetuloma b and (177)Lu-tetraxetan-rituximab. The absorbed radiation doses were extrapolated to human absorbed radiation doses. These extrapolated absorbed radiation doses to normal tissues for (177)Lu-tetraxetan-tetulomab at an injection of 40 MBq/kg were significantly lower than the absorbed radiation doses for 15 MBq/kg Zevalin, suggesting that higher tumor radiation dose can be reached with (177)Lu-tetraxetan-tetulomab in the clinic.

PubMed Disclaimer

Figures

Fig. (1)
Fig. (1)
Biodistribution (kBq/g) of 177Lu-tetulomab (A) and 177Lurituximab (B) in female nude mice with Daudi tumor xenografts. The data were normalized to an injected activity of 1 MBq per mouse (40 MBq/kg). Error bars correspond to standard error.
Fig. (2)
Fig. (2)
Dose rate (mGy/h) for key organs estimated from biodistributions of 177Lu-tetulomab (A) and 177Lu-rituximab (B) in nude mice with Daudi xenografts. The data were normalized to an injected activity of 1 MBq per mouse (40 MBq/kg). Error bars correspond to standard error.
Fig. (3)
Fig. (3)
Dose (Gy) to normal organs for mice with xenografts injected with 177Lu-tetulomab or 177Lu-rituximab. The data were normalized to an injected activity of 1 MBq per mouse (40 MBq/kg). Error bars correspond to standard error.
See this image and copyright information in PMC

References

    1. Foran JM, Norton AJ, Micallef IN, Taussig DC, Amess JA, Rohatiner AZ, Lister TA. Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20) a retrospective cohort analysis. Br. J. Haematol . 2001;114(4 ):881–883. - PubMed
    1. Sugimoto T, Tomita A, Hiraga J, Shimada K, Kiyoi H, Kinoshita T, Naoe T. Escape mechanisms from antibody therapy to lymphoma cells downregulation of CD20 mRNA by recruitment of the HDAC complex and not by DNA methylation. Biochem. Biophys Res. Commun . 2009;390(1 ):48–53. - PubMed
    1. Wada N, Kohara M, Ogawa H, Sugiyama H, Fukuhara S, Tatsumi Y, Kanamaru A, Hino M, Kanakura Y, Morii E, Aozasa K. Change of CD20 Expression in Diffuse Large B-Cell Lymphoma Treated with Rituximab, an Anti-CD20 Monoclonal Antibody: A Study of the Osaka Lymphoma Study Group. Case. Rep. Oncol . 2009;2(3 ):194–202. - PMC - PubMed
    1. Gopal AK, Press OW, Wilbur SM, Maloney DG, Pagel JM. Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab. Blood . 2008;112(3 ):830–835. - PMC - PubMed
    1. Moldenhauer G. CD37. J. Biol. Regul. Homeost. Agents. 2000;14(4 ):281–283. - PubMed

Publication types

LinkOut - more resources